c-Fms

<p>Mavrilimumab (CAM 3001), a monoclonal antibody, blocks GM-CSF signaling, potentially reducing inflammation in rheumatoid arthritis.</p>

<p>Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has</p>

<p>Edicotinib (JNJ-527) is a blood-brain permeable, selective CSF-1R inhibitor, with lesser inhibitory effects on KIT and FLT3.Cost-effective and quality-assured.</p>

Axatilimab (SNDX-6352) is a human IgG4 antibody that targets CSF-1R and can be used to study immune system diseases and respiratory diseases.

CSF1R-IN-1 is a CSF1R inhibitor with IC50 of 0.5 nM.

CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).

Lacnotuzumab (MCS110) is a humanized monoclonal antibody targeting CSF-1, which can be used in research on retinal diseases.

GENZ-882706(Raceme) is the racemate of GENZ-882706.

Eflapegrastim: humanized IgG4 antibody and G-CSF that boosts neutrophils and shortens neutropenia.

AMG-820 is a human antibody targeting CSF-1R, inhibiting the binding of ligands CSF1 and IL34, and preventing subsequent ligand-induced receptor activation. For AMG-820's isotype control, refer to [Human IgG2 kappa, Isotype Control].

Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.

Plonmarlimab(TJ003234) is an anti-GM-CSF monoclonal antibody with potential antiviral activity for the study of immune disorders and novel coronavirus infection

Balugrastim (CG 10639), a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF), results from the genetic fusion of recombinant human

Adrixetinib (TFA) is a protein tyrosine kinase inhibitor that possesses antineoplastic properties [1] [2] [3].

PD-360324 is a human monoclonal antibody (mAb) that targets CSF1/M-CSF. It can be utilized in research related to skin lupus, pulmonary sarcoidosis, and rheumatoid arthritis.

PXB17 inhibits CSF1R activation (IC50= 1.7 nM) by blocking the PI3K/AKT/mTORC1 signaling pathway. It is effective orally, significantly suppresses the growth of colorectal cancer (CRC), enhances the efficacy of PD-1 monoclonal antibodies (PD-1mAb), and reduces the recurrence of CRC tumors.

Sotuletinib hydrochloride (BLZ945 HCl) is a selective, brain-penetrant CSF-1R (c-Fms) inhibitor (IC50=1 nM),for ALS and TNBC.

PLX647 dihydrochloride: potent FMS/KIT inhibitor (IC50: 28/16 nM), highly selective, limited FLT3/KDR activity, oral use.

<p>Otilimab, a humanized monoclonal antibody, blocks GM-CSF to reduce inflammation and may treat severe COVID-19 pneumonia.</p>

Gimsilumab (MORAb-022) is an anti-c-Fms humanized monoclonal antibody for the study of inflammation and hypoxemia caused by COVID-19.